Drug Approval | November 21, 2025
Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
SOMA Color Mind is designed to simplify and accelerate color setup directly on the printing press
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
_256_384.png)
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The cleared system pairs a flexible nitinol implant with a deployable prong-locking mechanism, delivering rotational and length stability
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
